Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)

CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in acute severe hypertension cases.

Vial icon

Low-volume, non-weight-based dosing2

CLEVIPREX offers non-weight based dosing that is independent of renal or hepatic function.
Ready-to-use 50 mL and 100 mL vials are available for individualized, titratable administration.

Calculate Dosing
Cleviprex vials with dosing calculator
Efficacy Icon

Proven efficacy in clinical studies

  • Over 90% of patients with perioperative hypertension achieved treatment success (≥15% BP reduction from baseline)3,4
  • Low rate of overshoot in acute severe hypertension patients in the VELOCITY trial5

Time to effect icon

BP reduction within minutes2

In perioperative patients, CLEVIPREX produces a 4%–5% reduction in systolic blood pressure (SBP) within 2–4 minutes of initiation. An approximately 1–2 mg/hr increase will generally produce an additional 2–4 mmHg decrease in systolic pressure.

Safety Icon

Demonstrated safety profile

The safety profile of CLEVIPREX was evaluated in multiple clinical trials.2

CLEVIPREX videos for healthcare professionals

Get access to exclusive videos about CLEVIPREX presented by renowned anesthesiologist Dr. Horowitz.

Get information

Sign up to get information about CLEVIPREX or request communication from a Chiesi sales representative.

Contact a Chiesi sales representative